• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

克隆性造血与表观遗传衰老和临床结局相关。

Clonal hematopoiesis associated with epigenetic aging and clinical outcomes.

机构信息

Department of Pathology, Stanford University School of Medicine, Stanford, CA, USA.

Department of Human Genetics, David Geffen School of Medicine, University of California Los Angeles, Los Angeles, CA, USA.

出版信息

Aging Cell. 2021 Jun;20(6):e13366. doi: 10.1111/acel.13366. Epub 2021 May 29.

DOI:10.1111/acel.13366
PMID:34050697
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC8208788/
Abstract

Clonal hematopoiesis of indeterminate potential (CHIP) is a common precursor state for blood cancers that most frequently occurs due to mutations in the DNA-methylation modifying enzymes DNMT3A or TET2. We used DNA-methylation array and whole-genome sequencing data from four cohorts together comprising 5522 persons to study the association between CHIP, epigenetic clocks, and health outcomes. CHIP was strongly associated with epigenetic age acceleration, defined as the residual after regressing epigenetic clock age on chronological age, in several clocks, ranging from 1.31 years (GrimAge, p < 8.6 × 10 ) to 3.08 years (EEAA, p < 3.7 × 10 ). Mutations in most CHIP genes except DNA-damage response genes were associated with increases in several measures of age acceleration. CHIP carriers with mutations in multiple genes had the largest increases in age acceleration and decrease in estimated telomere length. Finally, we found that ~40% of CHIP carriers had acceleration >0 in both Hannum and GrimAge (referred to as AgeAccelHG+). This group was at high risk of all-cause mortality (hazard ratio 2.90, p < 4.1 × 10 ) and coronary heart disease (CHD) (hazard ratio 3.24, p < 9.3 × 10 ) compared to those who were CHIP-/AgeAccelHG-. In contrast, the other ~60% of CHIP carriers who were AgeAccelHG- were not at increased risk of these outcomes. In summary, CHIP is strongly linked to age acceleration in multiple clocks, and the combination of CHIP and epigenetic aging may be used to identify a population at high risk for adverse outcomes and who may be a target for clinical interventions.

摘要

克隆性造血(CHIP)是血液癌症的常见前体状态,大多数情况下是由于 DNA 甲基化修饰酶 DNMT3A 或 TET2 的突变引起的。我们使用来自四个队列的 DNA 甲基化阵列和全基因组测序数据,对 CHIP、表观遗传时钟和健康结果之间的关联进行了研究,这四个队列共有 5522 人。在几个时钟中,CHIP 与表观遗传年龄加速(定义为将表观遗传时钟年龄回归到实际年龄后的剩余年龄)强烈相关,范围从 1.31 岁(GrimAge,p<8.6×10)到 3.08 岁(EEAA,p<3.7×10)。除 DNA 损伤反应基因外,大多数 CHIP 基因的突变与多种加速老化的指标增加有关。多个基因发生突变的 CHIP 携带者,其年龄加速幅度最大,端粒长度估计值降低最大。最后,我们发现约 40%的 CHIP 携带者在 Hannum 和 GrimAge 中都有加速>0(称为 AgeAccelHG+)。与 CHIP-/AgeAccelHG-相比,该组发生全因死亡率(危险比 2.90,p<4.1×10)和冠心病(CHD)(危险比 3.24,p<9.3×10)的风险很高。相比之下,其余约 60%的 CHIP 携带者 AgeAccelHG-的这些结果没有增加的风险。总之,CHIP 与多个时钟中的年龄加速密切相关,CHIP 和表观遗传衰老的组合可用于识别发生不良结果风险较高的人群,这些人群可能是临床干预的目标。

https://cdn.ncbi.nlm.nih.gov/pmc/blobs/9b5a/8208788/2c4883af0eab/ACEL-20-e13366-g003.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/9b5a/8208788/fd863a2ee87b/ACEL-20-e13366-g001.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/9b5a/8208788/2c4883af0eab/ACEL-20-e13366-g003.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/9b5a/8208788/fd863a2ee87b/ACEL-20-e13366-g001.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/9b5a/8208788/2c4883af0eab/ACEL-20-e13366-g003.jpg

相似文献

1
Clonal hematopoiesis associated with epigenetic aging and clinical outcomes.克隆性造血与表观遗传衰老和临床结局相关。
Aging Cell. 2021 Jun;20(6):e13366. doi: 10.1111/acel.13366. Epub 2021 May 29.
2
[Aging and clonal hematopoesis.].[衰老与克隆性造血]。
Adv Gerontol. 2024;37(3):266-275.
3
The influences of DNA methylation and epigenetic clocks, on metabolic disease, in middle-aged Koreans.DNA 甲基化和表观遗传钟对中年韩国人代谢性疾病的影响。
Clin Epigenetics. 2020 Oct 15;12(1):148. doi: 10.1186/s13148-020-00936-z.
4
Clonal Hematopoiesis and Risk of Progression of Heart Failure With Reduced Left Ventricular Ejection Fraction.克隆性造血与左心室射血分数降低的心力衰竭进展风险。
J Am Coll Cardiol. 2021 Apr 13;77(14):1747-1759. doi: 10.1016/j.jacc.2021.02.028.
5
Clonal Hematopoiesis of Indeterminate Potential (CHIP) and Incident Type 2 Diabetes Risk.克隆性造血的不确定潜能 (CHIP) 与 2 型糖尿病发病风险。
Diabetes Care. 2023 Nov 1;46(11):1978-1985. doi: 10.2337/dc23-0805.
6
Association of Clonal Hematopoiesis of Indeterminate Potential With Inflammatory Gene Expression in Patients With Severe Degenerative Aortic Valve Stenosis or Chronic Postischemic Heart Failure.不确定潜能的克隆性造血与严重退行性主动脉瓣狭窄或慢性缺血性心力衰竭患者炎症基因表达的关系。
JAMA Cardiol. 2020 Oct 1;5(10):1170-1175. doi: 10.1001/jamacardio.2020.2468.
7
Clonal hematopoiesis of indeterminate potential, DNA methylation, and risk for coronary artery disease.克隆性造血不定潜能、DNA 甲基化与冠状动脉疾病风险。
Nat Commun. 2022 Sep 12;13(1):5350. doi: 10.1038/s41467-022-33093-3.
8
Supplemental Association of Clonal Hematopoiesis With Incident Heart Failure.补充性造血细胞克隆与心力衰竭事件的相关性。
J Am Coll Cardiol. 2021 Jul 6;78(1):42-52. doi: 10.1016/j.jacc.2021.04.085.
9
Dysfunctional epigenetic aging of the normal colon and colorectal cancer risk.正常结肠和结直肠癌风险的功能失调的表观遗传衰老。
Clin Epigenetics. 2020 Jan 3;12(1):5. doi: 10.1186/s13148-019-0801-3.
10
Clonal hematopoiesis of indeterminate potential in patients with acute coronary syndrome undergoing percutaneous coronary intervention in the absence of traditional risk factors.在无传统危险因素的急性冠状动脉综合征患者中接受经皮冠状动脉介入治疗时的不确定潜能克隆性造血。
Clin Res Cardiol. 2023 Apr;112(4):506-517. doi: 10.1007/s00392-022-02039-6. Epub 2022 Jun 15.

引用本文的文献

1
Haematopoietic ageing in health and lifespan.健康与寿命中的造血衰老
Nat Cell Biol. 2025 Aug 25. doi: 10.1038/s41556-025-01739-1.
2
Clonal Hematopoiesis of Intermediate Potential in Atrial Fibrillation: A Critical View of Current Knowledge as a Springboard for Future Research.心房颤动中具有中等潜能的克隆性造血:对当前知识的批判性审视作为未来研究的跳板
Diagnostics (Basel). 2025 Jul 30;15(15):1915. doi: 10.3390/diagnostics15151915.
3
Biological aging and incident cardiovascular diseases in individuals with diabetes: insights from a large prospective cohort study.

本文引用的文献

1
Cancer therapy shapes the fitness landscape of clonal hematopoiesis.癌症治疗改变了克隆性造血的适应性景观。
Nat Genet. 2020 Nov;52(11):1219-1226. doi: 10.1038/s41588-020-00710-0. Epub 2020 Oct 26.
2
Inherited causes of clonal haematopoiesis in 97,691 whole genomes.在 97691 个全基因组中发现的克隆性造血的遗传原因。
Nature. 2020 Oct;586(7831):763-768. doi: 10.1038/s41586-020-2819-2. Epub 2020 Oct 14.
3
Genetic Interleukin 6 Signaling Deficiency Attenuates Cardiovascular Risk in Clonal Hematopoiesis.遗传白细胞介素 6 信号缺陷可减轻克隆性造血的心血管风险。
糖尿病患者的生物衰老与心血管疾病发病:一项大型前瞻性队列研究的见解
Cardiovasc Diabetol. 2025 Aug 6;24(1):320. doi: 10.1186/s12933-025-02855-w.
4
Target practice: Opportunities for therapeutic intervention in CHIP and CCUS.靶向实践:CHIP和CCUS中的治疗干预机会。
Blood Rev. 2025 Jul 25:101323. doi: 10.1016/j.blre.2025.101323.
5
Clonal hematopoiesis in AML long-term survivors: Risk factors and clinical consequences.急性髓系白血病长期幸存者中的克隆性造血:危险因素及临床后果。
Hemasphere. 2025 Jul 24;9(7):e70183. doi: 10.1002/hem3.70183. eCollection 2025 Jul.
6
Biological age and clinical frailty scale measured at intensive care unit admission as predictors of hospital mortality among the critically ill in Western Australia: a retrospective cohort study.西澳大利亚重症患者入住重症监护病房时测量的生物学年龄和临床衰弱量表作为医院死亡率预测指标的回顾性队列研究。
Acute Crit Care. 2025 May;40(2):264-272. doi: 10.4266/acc.000200. Epub 2025 May 28.
7
Geroscience in heart failure: the search for therapeutic targets in the shared pathobiology of human aging and heart failure.心力衰竭中的老年科学:探寻人类衰老与心力衰竭共同病理生物学中的治疗靶点。
J Cardiovasc Aging. 2025;5(1). doi: 10.20517/jca.2024.15. Epub 2025 Jan 14.
8
Clonal hematopoiesis of indeterminate potential (CHIP) in cerebromicrovascular aging: implications for vascular contributions to cognitive impairment and dementia (VCID).脑微血管衰老中的不确定潜能克隆性造血(CHIP):对血管性认知障碍和痴呆(VCID)的影响
Geroscience. 2025 Apr 11. doi: 10.1007/s11357-025-01654-1.
9
Peripheral blood somatic mosaicism and clonal hematopoiesis across ancestry backgrounds.不同祖先背景下的外周血体细胞嵌合现象与克隆性造血
medRxiv. 2025 Mar 23:2025.03.21.25324408. doi: 10.1101/2025.03.21.25324408.
10
Clonal hematopoiesis: elements associated with clonal expansion and diseases.克隆性造血:与克隆性扩增及疾病相关的要素
Blood Res. 2025 Mar 13;60(1):17. doi: 10.1007/s44313-025-00065-7.
Circulation. 2020 Jan 14;141(2):124-131. doi: 10.1161/CIRCULATIONAHA.119.044362. Epub 2019 Nov 11.
4
Clonal hematopoiesis in human aging and disease.人类衰老和疾病中的克隆性造血
Science. 2019 Nov 1;366(6465). doi: 10.1126/science.aan4673.
5
Age-related clonal haemopoiesis is associated with increased epigenetic age.与年龄相关的克隆性造血与表观遗传年龄的增加有关。
Curr Biol. 2019 Aug 19;29(16):R786-R787. doi: 10.1016/j.cub.2019.07.011.
6
DNA methylation-based estimator of telomere length.基于DNA甲基化的端粒长度估计器。
Aging (Albany NY). 2019 Aug 18;11(16):5895-5923. doi: 10.18632/aging.102173.
7
DNA methylation GrimAge strongly predicts lifespan and healthspan.DNA甲基化GrimAge能有力地预测寿命和健康跨度。
Aging (Albany NY). 2019 Jan 21;11(2):303-327. doi: 10.18632/aging.101684.
8
Epigenetic clock for skin and blood cells applied to Hutchinson Gilford Progeria Syndrome and studies.应用于哈钦森-吉尔福德早衰综合征及相关研究的皮肤和血细胞表观遗传时钟。
Aging (Albany NY). 2018 Jul 26;10(7):1758-1775. doi: 10.18632/aging.101508.
9
An epigenetic biomarker of aging for lifespan and healthspan.一种用于寿命和健康寿命的衰老表观遗传生物标志物。
Aging (Albany NY). 2018 Apr 18;10(4):573-591. doi: 10.18632/aging.101414.
10
DNA methylation-based biomarkers and the epigenetic clock theory of ageing.基于 DNA 甲基化的生物标志物和衰老的表观遗传时钟理论。
Nat Rev Genet. 2018 Jun;19(6):371-384. doi: 10.1038/s41576-018-0004-3.